Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients

AIDS Research and Human Retroviruses

Volumn 15, Issue 6, 1999, Pages 533-543

  Spruth, Martin ^a   Stoiber, Heribert ^a   Kacani, Laco ^a   Schönitzer, Dieter ^b   Dierich, Manfred P ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Zentralinstitut F Bluttransfusion   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNITY; ALLOIMMUNIZATION; ARTICLE; COMPLEMENT ACTIVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIPID BILAYER; PRIORITY JOURNAL; SEROCONVERSION; TARGET CELL; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

BLOOD TRANSFUSION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HELA CELLS; HIV-1; HUMANS; IMMUNE SERA; ISOANTIBODIES; NEUTRALIZATION TESTS; TUMOR CELLS, CULTURED; U937 CELLS; VIRION;

EID: 0033541537     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311051     Document Type: Article

References (71)

1. Hoxie JA, Fitzharris TP, Youngbar PR, Matthews DM, Rackowski JL, and Radka SF: Nonrandom association of cellular antigens with HTLV-III virions. Hum Immunol 1987;18:39-52.
2. Gelderblom H, Reupke H, Winkel T, Kunze R, and Pauli G: MHC-antigens: Constituents of the envelopes of human and simian immunodeficiency viruses. Z Naturforsch C 1987;42:1328-1334.
3. Schols D, Pauwels R, Desmyter J, and De Clercq E: Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis. Virology 1992;189:374-376.
4. Arthur LO, Bess JW Jr, Sowder RC II, Benveniste RE, Mann DL, Chermann JC, and Henderson LE: Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science 1992;258:1935-1938.
5. Meerloo T, Sheikh MA, Bloem AC, de Ronde A, Schutten M, van Els CA, Roholl PJ, Joling P, Goudsmit J, and Schuurman HJ: Hot cell membrane proteins on human immunodeficiency virus type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscope study. J Gen Virol 1993;74:129-135.
6. Orentas RJ and Hildreth JE: Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res Hum Retroviruses 1993;9:1157-1165.
7. Saifuddin M, Ghassemi M, Patki C, Parker CJ, and Spear GT: Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res Hum Retroviruses 1994;10: 829-837.
8. Capobianchi MR, Fais S, Castilletti C, Gentile M, Ameglio F, and Dianzani F: A simple and reliable method to detect cell membrane proteins on infectious human immunodeficiency virus type 1 particles. J Infect Dis 1994;169:886-889.
9. Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, and Johnson PR: Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994;205:82-92.
10. Marschang P, Sodroski J, Wurzner R, and Dierich MP: Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 1995;25:285-290.
11. Abbate I, Capobianchi MR, Fais S, Castilletti C, Mercuri F, Cordiali Fei P, Ameglio F, and Dianzani F: Host cell antigenic profile acquired by HIV-1 is a marker of its cellular origin. Arch Virol 1995;140:1849-1854.
12. Cantin R, Fortin JF, and Tremblay M: The amount of host HLA-DR proteins acquired by HIV-1 is virus strain- and cell type-specific. Virology 1996;218:372-381.
13. Frank I, Stoiber H, Godar S, Stockinger H, Steindl F, Katinger HWD, and Dierich MP: Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 1996;10:1611-1620.
14. Saarloos MN, Sullivan BL, Czerniewski MA, Parameswar KD, and Spear GT: Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1. J Virol 1997;71:1640-1643.
15. Bastiani L, Laal S, Kim M, and Zollapazner S: Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol 1997;71:3444-3450.
16. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla Pazner S, Ghassemi M, Rooney IA, Atkinson JP, and Spear GT: Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995;182:501-509.
17. Stoiber H, Pinter C, Siccardi AG, Clivio A, and Dierich MP: Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 1996;183: 307-310.
18. Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, and Spear GT: Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 1997;78:1907-1911.
19. Guo MM and Hildreth JE: HIV acquires functional adhesion receptors from host cells. AIDS Res Hum Retroviruses 1995;11: 1007-1013.
20. Rossio JL, Bess J Jr, Henderson LE, Cresswell P, and Arthur LO: HLA class II on HIV particles is functional in superantigen presentation to human T cells: Implications for HIV pathogenesis. AIDS Res Hum Retroviruses 1995;11:1433-1439.
21. Fortin JF, Cantin R, Lamontagne G, and Tremblay M: Host-derived ICAm-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997;71:3588-3596.
22. Rizzuto CD and Sodroski JG: Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997;71:4847-4851.
23. Cantin R, Fortin JF, Lamontagne G, and Tremblay M: The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol 1997;71:1922-1930.
24. Corbeau P, Olive D, and Devaux C: Anti-HLA antigen class I heavy chain monoclonal antibodies inhibit human immunodeficiency virus production by peripheral blood mononuclear cells. Eur J Immunol 1991;21:865-871.
25. Kalter DC, Gendelman HE, and Meltzer MS: Inhibition of human immunodeficiency virus infection in monocytes by monoclonal antibodies against leukocyte adhesion molecules. Immunol Lett 1991;30:219-227.
26. Benkirane M, Blanc Zouaoui D, Hirn M, and Devaux C: Involvement of human leukocyte antigen class I molecules in human immunodeficiency virus infection of CD4-positive cells. J Virol 1994;68:6332-6339.
27. Gomez MB and Hildreth JE: Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1. J Virol 1995;69:4628-4632.
28. Stott EJ: Anti-cell antibody in macaques. Nature (London) 1991;353:393.
29. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, and Bolognesi DP: The ability of certain SIV vaccines to provoke reactions against normal cells. Science 1992;255:292-293.
30. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, and Bolognesi DP: Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retroviruses 1992;8:1641-1652.
31. Chan WL, Rodgers A, Hancock RD, Taffs F, Kitchin P, Farrar G, and Liew FY: Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J Exp Med 1992;176:1203-1207.
32. Cranage MP, Polyanskaya N, McBride B, Cook N, Ashworth LA, Dennis M, Baskerville A, Greenaway PJ, Corcoran T, Kitchin P, et al.: Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses 1993;9:13-22.
33. Bergmeier LA, Walker J, Tao L, Cranage M, and Lehner T: Antibodies to human and nonhuman primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus. Immunology 1994;83:213-220.
34. Chan WL, Rodgers A, Grief C, Almond N, Ellis S, Flanagan B, Silvera P, Bootman J, Stott J, Kent K, et al.: Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS 1995;9:223-228.
35. Arthur LO, Bess JW Jr, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, and Benveniste RE: Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 1995;69:3117-3124.
36. Shearer GM, Clerici M, and Dalgleish A: Alloimmunization as an AIDS vaccine? Science 1993;262:161-162.
37. Kiprov DD, Sheppard HW, and Hanson CV: Alloimmunization to prevent AIDS? Science 1994;263:737-738.
38. Peixinho ZF and Mendes NF: HLA antigens and resistance to HIV. J Clin Lab Anal 1994;8:456-458.
39. Haynes BF: HIV vaccines: Where we are and where we are going. Lancet 1996;348:933-937.
40. Luscher MA, Choy G, Njagi E, Bwayo JJ, Anzala AO, Ndinyaachola JO, Ball TB, Wade JA, Plummer FA, Barber BH, and MacDonald KS: Naturally occurring IgG anti-HLA alloantibody does not correlate with HIV type 1 resistance in Nairobi prostitutes. AIDS Res Hum Retroviruses 1998;14:109-115.
41. Luscher MA, Choy G, Embree JE, Nagelkerke NJD, Bwayo JJ, Njenga S, Plummer FA, Barber BH, and MacDonald KS: Anti-HLA alloantibody is found in children but does not correlate with a lack of HIV type 1 transmission from infected mothers. AIDS Res Hum Retroviruses 1998;14:99-107.
42. Polanskaya N, Sharpe S, Cook N, Leech S, Banks J, Dennis M, Hall G, Stott J, and Cranage M: Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection. AIDS Res Hum Retroviruses 1997;13: 923-931.
43. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67: 6642-6647.
44. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, et al.: A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994;10:1651-1658.
45. Akrigg A, Wilkinson GW, Angliss S, and Greenaway PJ: HIV-1 indicator cell lines. AIDS 1991;5:153-158.
46. Kerkau T, Schmitt Landgraf R, Schimpl A, and Wecker E: Downregulation of HLA class I antigens in HIV-1-infected cells. AIDS Res Hum Retroviruses 1989;5:613-620.
47. Larcher C, Julen N, Prodinger WM, Totsch M, Gurtler L, and Dierich MP: Reduced CD21 (CR2) and CD54 (ICAM-1) expression in MT2 cells with HIV-1 or HIV-2 strains. Immunol Lett 1995;46:31-36.
48. Noraz N, Verrier B, Fraisier C, and Desgranges C: Cell surface phenotypic changes induced in H9 T cells chronically infected with HTLV type I or HIV type 1 or coinfected with the two viruses. AIDS Res Hum Retroviruses 1995;11:145-154.
49. Pischel KD, Marlin SD, Springer TA, Woods VL Jr, and Bluestein HG: Polymorphism of lymphocyte function-associated antigen-1 demonstrated by a lupus patient's alloantiserum. J Clin Invest 1987;79:1607-1614.
50. Simsek S, van der Schoot CE, Daams M, Huiskes E, Clay M, McCullough J, van Dalen C, Stroncek D, and von dem Borne AE: Molecular characterization of antigenic polymorphisms (Ond(a) and Mart(a)) of the beta 2 family recognized by human leukocyte alloantisera. Blood 1996;88:1350-1358.
51. Plummer FA, Fowke K, Nagelkerke NJD, Simonsen JN, Bwayo J, Ngugi E, et al.: Evidence of resistance to HIV among continuously exposed prostitutes in Nairobi, Kenya. In IXth International Conference on AIDS, Berlin, June 6-11, 1993, Vol. 1, p. 23. [Abstract WS-A07-3]
52. Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, MacDonald KS, Ngugi EN, and Plummer FA: Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996;348:1347-1351.
53. MacDonald KS, Embree JE, Njenga S, Nagelkerke NJD, Ngatia I, Mohammed Z, Barber BH, Ndinya-Achola J, Bwayo J, and Plummer FA: Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 1998;177:551-556.
54. Haynes BF, Pantaleo G, and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328. [See comments]
55. Shearer GM and Clerici M: Protective immunity against HIV infection: Has nature done the experiment for us? Immunol Today 1996;17:21-24.
56. Mazzoli S, Trabattoni D, Caputo SL, Piconi S, Ble C, Meacci F, Ruzzante S, Salvi A, Semplici F, Longhi R, Fusi ML, Tofani N, Biasin M, Villa ML, Mazzotta F, and Clerici M: HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nature Med 1997;3:1250-1257.
57. Heeney JL, Bruck C, Goudsmit J, Montagnier L, Schultz A, Tyrrell D, and Zolla Pazner S: Immune correlates of protection from HIV infection and AIDS. Immunol Today 1997;18:4-8.
58. Paxton WA and Koup RA: Mechanisms of resistance to HIV infection. Springer Semin Immunopathol 1997;18:323-340.
59. Briant L, Benkirane M, Girard M, Hirn M, Iosef C, and Devaux C: Inhibition of human immunodeficiency virus type 1 production in infected peripheral blood mononuclear cells by human leukocyte antigen class I-specific antibodies: Evidence for a novel antiviral mechanism. J Virol 1996;70:5213-5220.
60. Beretta A, Grassi F, Pelagi M, Clivio A, Parravicini C, Giovinazzo G, Andronico F, Lopalco L, Verani P, Butto S, et al.: HIV Env glycoprotein shares a cross-reacting epitope with a surface protein present on activated human monocytes and involved in antigen presentation. Eur J Immunol 1987;17:1793-1798.
61. Golding H, Robey FA, Gates FT III, Linder W, Beining PR, Hoffman T, and Golding B: Identification of homologous regions in human immunodeficiency viras I gp41 and human MHC class II beta I domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. J Exp Med 1988;167:914-923.
62. Blackburn R, Clerici M, Mann D, Lucey DR, Goedert J, Golding B, Shearer GM, and Golding H: Common sequence in HIV 1 GP41 and HLA class II beta chains can generate crossreactive autoantibodies with immunosuppressive potential early in the course of HIV 1 infection. Adv Exp Med Biol 1991;303:63-69.
63. Lopalco L, De Santis C, Meneveri R, Longhi R, Ginelli E, Grassi F, Siccardi AG, and Beretta A: Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I alpha 1 peptide-binding domain. Eur J Immunol 1993;23:2016-2021.
64. De Santis C, Robbioni P, Longhi R, Lopalco L, Siccardi AG, Beretta A, and Roberts NJ Jr: Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines. J Infect Dis 1993;168:1396-1403.
65. De Santis C, Lopalco L, Robbioni P, Longhi R, Rappocciolo G, Siccardi AG, and Beretta A: Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells. AIDS Res Hum Retroviruses 1994;10:157-162.
66. Golding H, Shearer GM, Hillman K, Lucas P, Manischewitz J, Zajac RA, Clerici M, Gress RE, Boswell RN, and Golding B: Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest 1989;83:1430-1435.
67. Borghi MO, De Santis C, Barcellini W, Lopalco L, Fain C, Lazzarin A, Siccardi AG, Meroni PL, Zanussi C, and Beretta A: Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients. J Acquir Immune Defic Syndr 1993;6:1114-1119.
68. Spear GT, Sullivan BL, Landay AL, and Lint TF: Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol 1990;64:5869-5873.
69. Sullivan BL, Takefman DM, and Spear GT: Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology 1998;248:173-181.
70. Lamm ME: Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 1997;51:311-340.
71. Hocini H, Belec L, Iscaki S, Garin B, Pillot J, Becquart P, and Bomsel M: High-level ability of secretory IgA to block HIV type 1 trancytosis: Contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses 1997;13:1179-1185.